Peptide materials & custom synthesisLyophilized powder · Microneedle patches · Oral films & pouchesOEM · ODM · CRO · CDMO project supportDiscuss your product, packaging & target market
INSIGHTS

Residual solvent testing for peptide raw materials: an ICH Q3C guide

October 30, 2026

Residual solvent testing for peptide raw materials: an ICH Q3C guide

By PeptideVaultPro · Analytical procurement editorial · Sources checked 31 October 2026

Build a residual-solvent specification from the manufacturing route, the intended use and a method capable of testing the relevant solvents. A peptide HPLC purity figure cannot replace solvent-specific evidence. Any ICH limit used in the specification needs its pharmaceutical scope and calculation basis stated.

Start with the solvents the material actually encounters

Ask the supplier for a process-relevant solvent assessment. For a peptide project, the review should identify solvents introduced during the applicable synthesis, purification and finishing operations. The agreed assessment can explain which solvents require testing and which are excluded with a documented reason. A short generic panel should have a clear relationship to that route.

Keep the route review under change control. If a supplier changes a purification solvent, the old panel may no longer answer the purchasing question. Request enough process information to review the risk without requiring disclosure of an entire proprietary synthesis record.

Separate the different impurity questions

Set up independent specification lines for peptide-related impurities, residual organic solvents, counterions and any relevant elemental impurities. Each line needs a purpose and an appropriate analytical basis. The counterion review guide explains why an acetate or trifluoroacetate description needs its own evidence.

What ICH Q3C numbers mean in context

ICH Q3C(R9) addresses residual solvents in pharmaceuticals. Its Option 1 concentration limits use a 10 g daily product-mass assumption. For example, Table 2 lists acetonitrile at 410 ppm with a permitted daily exposure of 4.1 mg/day, and methanol at 3,000 ppm with a permitted daily exposure of 30 mg/day. These are guideline reference values, not results for any product offered on this site. EMA: ICH Q3C(R9), Option 1 and Table 2.

Reference solvent Q3C class Option 1 concentration Context required
Acetonitrile Class 2 410 ppm Pharmaceutical guideline; stated calculation assumptions apply.
Methanol Class 2 3,000 ppm Pharmaceutical guideline; assess the complete applicable control strategy.

The reference values help explain a supplier’s report. They do not establish a universal specification for cosmetic ingredients, food ingredients or research materials. Have the responsible quality and regulatory team select the applicable requirements for the product and destination market. Record the guideline revision used, because a quotation that simply says “ICH compliant” leaves that choice unclear.

A numerical example for comparing units

On a mass basis, 1 ppm equals 1 mg/kg. A hypothetical report of 100 mg/kg therefore reports 100 ppm, provided both expressions use the same sample basis. This arithmetic example says nothing about whether the batch is acceptable. An acceptance decision also needs the specified solvent, intended use, relevant limit and reporting method.

Read a residual-solvent report as an analytical record

Request a report tied to the offered batch. It should identify the solvents measured, individual results, units, method reference and relevant reporting limits. Ask how the laboratory deals with the peptide matrix, particularly if the sample preparation or test method differs from the method used for earlier batches.

Q3C discusses pharmacopoeial and appropriately validated analytical procedures, with gas chromatography commonly used for residual-solvent determination. Method selection still depends on the analytes and sample. A headspace GC result is useful only when the method can answer the specified question at the required level. ICH Q3C(R9): analytical procedures.

  • Check that the sample identity and lot match the quotation.
  • Compare each reporting limit with the corresponding acceptance criterion.
  • Resolve “not detected,” “below quantification” and numerical results separately.
  • Ask whether the result is on the as-received material or another defined basis.
  • Request review when the route, laboratory or method changes.

Where elemental impurities fit

ICH Q3D(R2) provides a separate risk-based framework for elemental impurities in drug products. Its exposure limits and assessment approach answer a different question from the residual-solvent panel. The existence of a solvent report does not document an elemental-impurity assessment. EMA: ICH Q3D elemental impurities.

For an initial supplier review, create a one-page matrix listing each impurity concern, the process reason it is relevant, the proposed evidence and the person responsible for approval. This gives procurement a practical way to follow unresolved items through sampling and quotation. Keep unsupported compliance statements out of the approval column.

Frequently asked questions

Does high peptide purity mean low residual solvents?

A peptide purity result does not supply individual residual-solvent concentrations. Request the process assessment and solvent-specific test evidence needed for the purchasing specification.

Are the ICH numbers automatic limits for research peptides?

ICH Q3C has a pharmaceutical scope. A research-material specification must be selected for its permitted use and project requirements; citing an ICH value does not make the material suitable for human use.

Can “not detected” be accepted without a reporting threshold?

Ask for the relevant detection or reporting limit and method basis. Without that information, the phrase does not show whether the test could assess your acceptance criterion.

Must every conceivable solvent be tested?

Use a justified assessment of the applicable route and requirements. Document the reasoning behind the test panel, including any exclusions, and revisit it after relevant process changes.

Sources and scope

This is a supplier-review framework, not a batch release assessment or a statement of PeptideVaultPro test capability. Confirm document availability for the specific enquiry.

Continue with testing responsibilities in a quality agreement or request technical documentation for an offered material.

Discuss a related project →